GRAIL (GRAL) Expected to Announce Quarterly Earnings on Thursday

GRAIL (NASDAQ:GRAL) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect GRAIL to post earnings of ($3.33) per share and revenue of $43.3330 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 19, 2026 at 5:00 PM ET.

GRAIL Stock Performance

Shares of GRAL stock opened at $97.50 on Tuesday. The stock has a market capitalization of $3.80 billion, a P/E ratio of -8.38 and a beta of 4.52. The company has a 50 day moving average price of $97.12 and a 200 day moving average price of $74.98. GRAIL has a fifty-two week low of $20.44 and a fifty-two week high of $118.84.

Institutional Trading of GRAIL

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Comerica Bank boosted its holdings in shares of GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after buying an additional 173 shares in the last quarter. Intesa Sanpaolo S.p.A. purchased a new stake in GRAIL in the fourth quarter valued at $44,000. NewEdge Advisors LLC boosted its stake in GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after acquiring an additional 1,401 shares in the last quarter. Ankerstar Wealth LLC purchased a new position in shares of GRAIL during the fourth quarter worth about $45,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of GRAIL by 28.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after purchasing an additional 623 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Guggenheim increased their price objective on GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Thursday, January 22nd. Morgan Stanley boosted their price objective on GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Finally, Canaccord Genuity Group raised their target price on shares of GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a report on Monday, November 17th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, GRAIL has a consensus rating of “Hold” and a consensus price target of $105.00.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.